Alnylam Pharmaceuticals
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $773,689 | $594,189 | $593,166 | $500,919 |
Gross Profit | 630,736 | 523,148 | 490,349 | 415,014 |
EBITDA | 18,832 | 11,455 | -140,911 | -60,305 |
EBIT | 4,888 | -2,950 | -155,079 | -74,287 |
Net Income | -66,277 | -57,479 | -83,763 | -111,570 |
Net Change In Cash | 773,689 | 594,189 | 593,166 | 500,919 |
Free Cash Flow | 139,437 | -127,284 | -103,756 | 39,515 |
Cash | 1,113,685 | 1,019,654 | 966,428 | 1,099,920 |
Basic Shares | 129,676 | 129,676 | 128,590 | 128,590 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $2,248,243 | $1,828,292 | $1,037,418 | $844,287 |
Gross Profit | 1,924,873 | 1,517,886 | 868,601 | 704,143 |
EBITDA | -178,847 | -258,242 | -926,557 | -661,556 |
EBIT | -235,517 | -312,296 | -971,025 | -709,123 |
Net Income | -278,157 | -440,242 | -1,131,156 | -852,824 |
Net Change In Cash | 2,248,243 | 1,828,292 | 1,037,418 | 844,287 |
Cost of Revenue | 53,833 | 332,125 | ||
Free Cash Flow | -42,589 | 41,945 | -613,333 | -718,065 |
Cash | 966,428 | 812,688 | 866,394 | 819,975 |
Basic Shares | 127,651 | 124,906 | 121,689 | 118,451 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0 |
2025-06-30 | -$0.51 |
2025-03-31 | -$0.01 |
2024-12-31 | $0.06 |
